ArticleCell reports2022
SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract.
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Chronic lung inflammation and CK14+ basal cell proliferation induce persistent alveolar-bronchiolization in SARS-CoV-2-infected hamsters.EBioMedicine · 2024Article
- Olfactory immunology: the missing piece in airway and CNS defence.Nature reviews. Immunology · 2024Review
- Pathogenicity and virulence of henipaviruses.Virulence · 2023Review
- Omicron breakthrough infections in vaccinated or previously infected hamsters.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Infection- or AZD1222 vaccine-mediated immunity reduces SARS-CoV-2 transmission but increases Omicron competitiveness in hamsters.Nature communications · 2023Article
- Previous infection with seasonal coronaviruses does not protect male Syrian hamsters from challenge with SARS-CoV-2.Nature communications · 2023Article
- A non-transmissible live attenuated SARS-CoV-2 vaccine.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes.Viruses · 2023Article
- Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters.Journal of virology · 2023Article
- Longitudinal analysis of SARS-CoV-2 reinfection reveals distinct kinetics and emergence of cross-neutralizing antibodies to variants of concern.Frontiers in microbiology · 2023Article
- Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters.Emerging microbes & infections · 2022Article
- Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models.Science (New York, N.Y.) · 2022Article
- Infection- or vaccine mediated immunity reduces SARS-CoV-2 transmission, but increases competitiveness of Omicron in hamsters.bioRxiv : the preprint server for biology · 2022Article
- Article
- Mosaic RBD nanoparticles protect against multiple sarbecovirus challenges in animal models.bioRxiv : the preprint server for biology · 2022Article
- SARS-CoV2 variant-specific replicating RNA vaccines protect from disease and pathology and reduce viral shedding following challenge with heterologous SARS-CoV2 variants of concern.bioRxiv : the preprint server for biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
Abstract
Human cases of SARS-CoV-2 reinfection have been documented throughout the pandemic, but are likely under-reported. In the current study, we use the Syrian hamster SARS-CoV-2 model to assess reinfection with homologous WA1 and heterologous B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants over time. Upon primary infection with SARS-CoV-2 WA1, hamsters rapidly develop a strong and long-lasting humoral immune response. After reinfection with homologous and heterologous SARS-CoV-2 variants, this immune response protects hamsters from clinical disease, virus replication in the lower respiratory tract, and acute lung pathology. However, reinfection leads to SARS-CoV-2 replication in the upper respiratory tract with the potential for virus shedding. Our findings indicate that reinfection results in restricted SARS-CoV-2 replication despite substantial levels of humoral immunity, denoting the potential for transmission through reinfected asymptomatic individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.